Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Preserved Ejection Fraction: a Randomized, Double-blind, Basic-treatment-loading, Placebo-controlled, Multicenter Phase Ⅱ Clinical Trial

NCT04944706 is registered in ClinicalTrials.gov with Tasly Pharmaceutical Group Co., Ltd as lead sponsor.

NCT NCT04944706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04944706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Preserved Ejection Fraction: a Randomized, Double-blind, Basic-treatment-loading, Placebo-controlled, Multicenter Phase Ⅱ Clinical Trial
Lead sponsor
Tasly Pharmaceutical Group Co., Ltd
Phase
Phase 2
Overall status
Completed
Start date
July 27, 2021
Completion date
December 19, 2024
Enrollment
225 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

chronic heart failure with preserved ejection fraction